Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Wednesday, May 24, 2023, at 2 p.m. , at 1 rue Lafaurie de Mondabon, 33000 Bordeaux . The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions...